Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis

Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis

To investigate the effects of prior treatment and the predictors of early treatment response to romosozumab (ROMO) in patients with postmenopausal osteoporosis. In this prospective, observational, multicenter study, 130 treatment-naïve patients (Naïve; n = 37) or patients previously treated with bis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone (New York, N.Y.) N.Y.), 2020-11, Vol.140, p.115574-115574, Article 115574
Hauptverfasser: Ebina, Kosuke, Hirao, Makoto, Tsuboi, Hideki, Nagayama, Yoshio, Kashii, Masafumi, Kaneshiro, Shoichi, Miyama, Akira, Nakaya, Hiroyuki, Kunugiza, Yasuo, Okamura, Gensuke, Etani, Yuki, Takami, Kenji, Goshima, Atsushi, Nakata, Ken
Format: Artikel
Sprache:eng
Schlagworte:
Bone turnover marker
Postmenopausal osteoporosis
Predictor
Prior treatment
Romosozumab
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To investigate the effects of prior treatment and the predictors of early treatment response to romosozumab (ROMO) in patients with postmenopausal osteoporosis. In this prospective, observational, multicenter study, 130 treatment-naïve patients (Naïve; n = 37) or patients previously treated with bisphosphonates (BP; n = 33), denosumab (DMAb; n = 45), or teriparatide (TPTD; n = 15) (age, 75.0 years; T-scores of the lumbar spine [LS] −3.2 and femoral neck [FN] −2.9) were switched to ROMO based on their physician's decision. Bone mineral density (BMD) and serum bone turnover markers were evaluated for six months. At six months, LS BMD changes were 13.6%, 7.5%, 3.6%, and 8.7% (P 
ISSN:8756-3282
1873-2763
DOI:10.1016/j.bone.2020.115574